You have 3 free articles left this month. Get your free Basic subscription now and gain instant access to more.

Croatia's Optimapharm acquires Greece's Qualitis

Author Annie Tsoneva
Croatia's Optimapharm acquires Greece's Qualitis Photo: Vetprom / All rights reserved.

ZAGREB (Croatia), June 29 (SeeNews) - Croatian clinical research organization (CRO) Optimapharm said it has acquired Greece-based clinical research and medical consulting organization Qualitis to reinforce its position as a medium-sized European market leader, and extend its geographical presence with an office in Athens.

“This acquisition will complement Optimapharm’s geographic coverage and significantly strengthen Optimapharm’s presence in southern Europe. With the acquisition of Qualitis, Optimapharm expands its operational team, providing best-in-class, tailor-made clinical research solutions to biotech, pharma, and medical device clients worldwide,” the Zagreb-based company said in a press release on Monday.

You can subscribe to our M&A newsletter here

It did not disclose the value of the deal.

Optimapharm is a full-service CRO that manages clinical trials across Europe and currently conducts more than 310 trials in over 40 countries. It was set up in 2006 in Zagreb and operates through 26 offices in strategic locations across Europe and conducts operational activities in 14 additional countries. Optimapharm conducts phase I – IV studies in all therapeutic areas with a specific focus on oncology, neurosciences, cardiology, endocrinology, and infectious diseases.

Qualitis is a full-service CRO offering a comprehensive portfolio of clinical development and medical consulting services to the pharmaceutical, biotechnology and medical device industries. Optimapharm has more than 510 employees.

The acquisition of Qualitis, follows the recent acquisition of Romanian Clinical Trials Group, German SSS International Clinical Research, and Finnish Crown CRO in the past 12 months and the acquisition of Spanish Syntax for Science, in 2020.

 

Share this story
SeeNews in Brief

View our Newsletters

 
Compare